Core Viewpoint - The company, 医脉通 (02192.HK), reported significant revenue growth and profitability for the six months ending June 30, 2025, indicating strong performance in the AI healthcare sector [1] Financial Performance - Revenue reached RMB 312 million, a year-on-year increase of 28.2% [1] - Gross profit was RMB 184 million, reflecting a 24.9% increase compared to the previous year [1] - Net profit attributable to the parent company was RMB 155 million, up 5.9% year-on-year [1] - Adjusted net profit under non-Hong Kong Financial Reporting Standards was RMB 167 million, an increase of 6.9% [1] - Basic earnings per share were RMB 0.212 [1] Dividend Announcement - The board of directors declared an interim dividend of RMB 0.1166 per ordinary share [1] Business Solutions - The company generated revenue through three main solutions: precision marketing and enterprise solutions, medical knowledge solutions, and intelligent patient management solutions [1] - The company maintained a high net profit margin of 51.4% during the reporting period [1] - Adjusted net profit margin was 53.4%, reinforcing the company's leading position in the AI healthcare industry [1]
医脉通(02192.HK)：上半年经调整净溢利为1.67亿元 同比增加6.9%